

Patient Information

Specimen Information

# SAMPLE REPORT #1

*Microbial load presented in Colony Forming Units per mL (CFU/mL) to aid in accurate treatment guidance.*

## Panel: Urinary Tract Infection(UTI)

Organism(s) Detected	Results	Qualitative (High / Medium / Low)	Est. Microbial Load* (CFU/mL)
Acinetobacter baumannii	Detected	Medium	$10^4 - 10^5$
Aerococcus urinae	Detected	Low	$<10^4$
Enterobacter cloacae	Detected	High	$>10^5$
Enterococcus faecalis	Detected	Medium	$10^4 - 10^5$
Escherichia coli	Detected	High	$>10^5$
Klebsiella pneumoniae	Detected	High	$>10^5$

## Panel: Antibiotic Resistance Genes

Resistance Gene(s) Detected	Antibiotic Class	Results
ampC	Beta-Lactamase - Class C Type	Beta Lactam Resistance Detected
TEM	Beta-Lactamase - Class A Type	Beta Lactam Resistance Detected
QnrA, QnrS, Qnr B	Fluoroquinolones	Quinolone Resistance Detected
Sul1, Sul2	Sulfonamide (Sulfamethoxazole)	Sulfonamide Resistance Detected
BIL/LAT/CMY	Beta-Lactamase - Class C Type	Beta Lactam Resistance Detected
SHV	Beta-Lactamase - Class A Type	Beta Lactam Resistance Detected

*Detailed Antibiotic Resistance Genes report*

### ANTIBIOTIC TREATMENT OPTIONS

Medication	Acinetobacter baumannii	Aerococcus urinae	Enterobacter cloacae	Enterococcus faecalis	Escherichia coli	Klebsiella pneumoniae
Fosfomycin	S		S		S	S
Amoxicillin						
Amoxicillin-Clavulanate						
Ampicillin						
Azithromycin						
Cefadroxil						
Cefdinir						
Cefixime						
Cefuroxime						
Cephalexin						
Cephalosporins				S		
Ciprofloxacin						

*Effective antibiotic treatment guidance report helps the physician select the proper medication for the detected pathogens.*

Medication	Acinetobacter baumannii	Aerococcus urinae	Enterobacter cloacae	Enterococcus faecalis	Escherichia coli	Klebsiella pneumoniae
Clindamycin						
Doxycycline						
Erythromycin						
Fluconazole						
Levofloxacin						
Linezolid				S		
Nitrofurantoin	S		S		S	S
Ofloxacin						
Rifampin		S				
Sulfamethoxazole/Trimethoprim						
Tetracycline				S		
Trimethoprim/Sulfa						
Vancomycin				S		

Final Report Electronically signed by: on 01/04/2022 at 02:46 PM

**Laboratory Director:** Dr. Nicole Massoll, M.D.



This test performed by Promus Diagnostics LLC, 2300 Dean Way, Suite 130, Southlake, TX 76092 CLIA#: 45D2156626; CAP#: 8412352

Please note: The semi-quantitative results for this test are based on estimates from internal validation studies performed at Promus Diagnostics and the scientific literature. These are intended to aid in guiding diagnostic and therapeutic decisions. Because of the increased sensitivity of PCR amplification used in this test compared to microbial culture, these results (genome copies / ml) may be a more accurate estimate of the actual concentration of pathogens than the results from agar-based cultures. However, treatment protocols should be based on the patients clinical history, all associated laboratory test results, and the Guidelines from the Infectious Disease Society of America (IDSA) Nicole LE et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. Clin Infect Dis 2019 Mar 21;[e-pub]. (<https://doi.org/10.1093/cid/ciy1121>). This test was developed and its performance characteristics determined by Promus Diagnostics, LLC. It has not been cleared or approved by the FDA. However, such approval/ clearance is not required, as the laboratory is regulated and qualified under CLIA to perform High - Complexity testing. This test is used for clinical purposes, and should not be regarded as investigational or for research

The treatment guidance listed in the report is based upon infectious disease treatment references, the organisms detected, and genes known to contribute to medication resistance. Important clinical information such as comorbidities, renal function, patient weight, platelet count, microbiology results, etc. may influence the overall appropriateness of therapy. The provided guidance only takes drug allergies into account when they are provided and available to the pharmacist making the recommendation. The overall appropriateness of therapy must be determined by the physician treating the patient. The provider has all the information necessary to make that determination and should take the entire clinical presentation into account when making treatment decisions. Should the treating physician wish to discuss the provided guidance, the pharmacist is available for consult at the email and phone number provided.

Name: 1, Positive

Lab Accession Number: D220030026 DOB: 1/1/2018

Report Date: 1/4/2022

# Tested Assay Results

## Panel: Urinary Tract Infection(UTI)

Organism	Results	Qualitative	Normal Reference Range
<b>Acinetobacter baumannii</b>	<b>Detected</b>	<b>Medium</b>	10 <sup>4</sup> - 10 <sup>5</sup>
Actinobaculum schaalii	Not Detected	Negative	Not Detected
<b>Aerococcus urinae</b>	<b>Detected</b>	<b>Low</b>	<10 <sup>4</sup>
Alloscardovia Omnicolens	Not Detected	Negative	Not Detected
Candida albicans	Not Detected	Negative	Not Detected
Candida auris	Not Detected	Negative	Not Detected
Candida glabrata	Not Detected	Negative	Not Detected
Candida parapsilosis	Not Detected	Negative	Not Detected
Citrobacter freundii	Not Detected	Negative	Not Detected
Citrobacter koseri	Not Detected	Negative	Not Detected
Coagulase Negative Staph	Not Detected	Negative	Not Detected
Corynebacterium riegelii	Not Detected	Negative	Not Detected
Enterobacter aerogenes	Not Detected	Negative	Not Detected
<b>Enterobacter cloacae</b>	<b>Detected</b>	<b>High</b>	>10 <sup>5</sup>
<b>Enterococcus faecalis</b>	<b>Detected</b>	<b>Medium</b>	10 <sup>4</sup> - 10 <sup>5</sup>
Enterococcus faecium	Not Detected	Negative	Not Detected
<b>Escherichia coli</b>	<b>Detected</b>	<b>High</b>	>10 <sup>5</sup>
Klebsiella oxytoca	Not Detected	Negative	Not Detected
<b>Klebsiella pneumoniae</b>	<b>Detected</b>	<b>High</b>	>10 <sup>5</sup>
Morganella morganii	Not Detected	Negative	Not Detected
Mycoplasma hominis	Not Detected	Negative	Not Detected
Pantoea agglomerans	Not Detected	Negative	Not Detected
Proteus mirabilis	Not Detected	Negative	Not Detected
Proteus vulgaris	Not Detected	Negative	Not Detected
Providencia stuartii	Not Detected	Negative	Not Detected
Pseudomonas aeruginosa	Not Detected	Negative	Not Detected
Serratia marcescens	Not Detected	Negative	Not Detected
Staphylococcus aureus	Not Detected	Negative	Not Detected
Streptococcus agalactiae	Not Detected	Negative	Not Detected
Ureaplasma urealyticum	Not Detected	Negative	Not Detected
Viridans Group Strep	Not Detected	Negative	Not Detected
Bacillus atrophaeus	Not Detected	Negative	Not Detected

This test performed by Promus Diagnostics LLC, 2300 Dean Way, Suite 130, Southlake, TX 76092 CLIA#: 45D2156626; CAP#: 8412352

Please note: The semi-quantitative results for this test are based on estimates from internal validation studies performed at Promus Diagnostics and the scientific literature. These are intended to aid in guiding diagnostic and therapeutic decisions. Because of the increased sensitivity of PCR amplification used in this test compared to microbial culture, these results (genome copies / ml) may be a more accurate estimate of the actual concentration of pathogens than the results from agar-based cultures. However, treatment protocols should be based on the patients clinical history, all associated laboratory test results, and the Guidelines from the Infectious Disease Society of America (IDSA) Nicole LE et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. Clin Infect Dis 2019 Mar 21;[e-pub]. (https://doi.org/10.1093/cid/ciy1121). This test was developed and its performance characteristics determined by Promus Diagnostics, LLC. It has not been cleared or approved by the FDA. However, such approval/ clearance is not required, as the laboratory is regulated and qualified under CLIA to perform High - Complexity testing. This test is used for clinical purposes, and should not be regarded as investigational or for research

The treatment guidance listed in the report is based upon infectious disease treatment references, the organisms detected, and genes known to contribute to medication resistance. Important clinical information such as comorbidities, renal function, patient weight, platelet count, microbiology results, etc. may influence the overall appropriateness of therapy. The provided guidance only takes drug allergies into account when they are provided and available to the pharmacist making the recommendation. The overall appropriateness of therapy must be determined by the physician treating the patient. The provider has all the information necessary to make that determination and should take the entire clinical presentation into account when making treatment decisions. Should the treating physician wish to discuss the provided guidance, the pharmacist is available for consult at the email and phone number provided.

This test was developed and its performance characteristics determined by Promus Diagnostics LLC. It has not been cleared or approved by the FDA. However, such approval/clearance is not required, as the laboratory is regulated and qualified under CLIA to perform high-complexity testing. This test is used for clinical purposes, and should not be regarded as investigational or for research.

This test performed by Promus Diagnostics LLC, 2300 Dean Way, Suite 130, Southlake, TX 76092 CLIA#: 45D2156626; CAP#: 8412352

Please note: The semi-quantitative results for this test are based on estimates from internal validation studies performed at Promus Diagnostics and the scientific literature. These are intended to aid in guiding diagnostic and therapeutic decisions. Because of the increased sensitivity of PCR amplification used in this test compared to microbial culture, these results (genome copies / ml) may be a more accurate estimate of the actual concentration of pathogens than the results from agar-based cultures. However, treatment protocols should be based on the patient's clinical history, all associated laboratory test results, and the Guidelines from the Infectious Disease Society of America (IDSA) - Nicolle LE et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. Clin Infect Dis 2019 Mar 21; [e-pub]. (<https://doi.org/10.1093/cid/ciy1121>). This test was developed and its performance characteristics determined by Promus Diagnostics, LLC. It has not been cleared or approved by the FDA. However, such approval/clearance is not required, as the laboratory is regulated and qualified under CLIA to perform High - Complexity testing. This test is used for clinical purposes, and should not be regarded as investigational or for research.

The treatment guidance listed in the report is based upon infectious disease treatment references, the organisms detected, and genes known to contribute to medication resistance. Important clinical information such as comorbidities, renal function, patient weight, platelet count, microbiology results, etc. may influence the overall appropriateness of therapy. The provided guidance only takes drug allergies into account when they are provided and available to the pharmacist making the recommendation. The overall appropriateness of therapy must be determined by the physician treating the patient. The provider has all the information necessary to make that determination and should take the entire clinical presentation into account when making treatment decisions. Should the treating physician wish to discuss the provided guidance, the pharmacist is available for consult at the email and phone number provided.

This test was developed and its performance characteristics determined by Promus Diagnostics LLC. It has not been cleared or approved by the FDA. However, such approval/clearance is not required, as the laboratory is regulated and qualified under CLIA to perform high-complexity testing. This test is used for clinical purposes, and should not be regarded as investigational or for research.

Name: 1, Positive

Lab Accession Number: D220030026 DOB: 1/1/2018

Report Date: 1/4/2022

# Tested Assay Results

## Panel: Antibiotic Resistance Genes

Resistance Gene(s)	Antibiotic Class	Results	Normal Reference Range
<b>ampC</b>	<b>Beta-Lactamase - Class C Type</b>	<b>Detected</b>	Not Detected
DHA	Beta-Lactamase - Class C Type	Not Detected	Not Detected
IMP-1 group, IMP-16, IMP-7	Beta-Lactamase - Class B Type	Not Detected	Not Detected
OXA-23, OXA-72, OXA-40, blaOXA-48	Beta-Lactamase - Class D Type (Carbapenemase / Oxacillinase)	Not Detected	Not Detected
VIM	Beta-Lactamase - Class B Type	Not Detected	Not Detected
CTX-M group 1, CTX-M group 2, CTX-M group 9, CTX-M group 8/25	Beta-Lactamase - Class A Type	Not Detected	Not Detected
OXA-1, GES, PER-1, PER-2	Extended Spectrum BetaLactamase - Class A	Not Detected	Not Detected
PER-1, PER-2	Extended Spectrum BetaLactamase - Class A	Not Detected	Not Detected
<b>TEM</b>	<b>Beta-Lactamase - Class A Type</b>	<b>Detected</b>	Not Detected
mecA	Methicillin	Not Detected	Not Detected
<b>QnrA, QnrS, Qnr B</b>	<b>Fluoroquinolones</b>	<b>Detected</b>	Not Detected
vanA1, vanA2, vanB	Vancomycin	Not Detected	Not Detected
dfrA5, dfrA1	Trimethoprim	Not Detected	Not Detected
<b>Sul1, Sul2</b>	<b>Sulfonamide (Sulfamethoxazole)</b>	<b>Detected</b>	Not Detected
nfsA	Nitrofurantoin	Not Detected	Not Detected
FOX	Beta-Lactamase - Class C Type	Not Detected	Not Detected
ACC	Beta-Lactamase - Class C Type	Not Detected	Not Detected
MOX/CMY	Beta-Lactamase - Class C Type	Not Detected	Not Detected
<b>BIL/LAT/CMY</b>	<b>Beta-Lactamase - Class C Type</b>	<b>Detected</b>	Not Detected
<b>SHV</b>	<b>Beta-Lactamase - Class A Type</b>	<b>Detected</b>	Not Detected
VEB	Extended Spectrum BetaLactamase - Class A	Not Detected	Not Detected
KPC	Beta-Lactamase - Class A Type	Not Detected	Not Detected

This test performed by Promus Diagnostics LLC, 2300 Dean Way, Suite 130, Southlake, TX 76092 CLIA#: 45D2156626; CAP#: 8412352

Please note: The semi-quantitative results for this test are based on estimates from internal validation studies performed at Promus Diagnostics and the scientific literature. These are intended to aid in guiding diagnostic and therapeutic decisions. Because of the increased sensitivity of PCR amplification used in this test compared to microbial culture, these results (genome copies / ml) may be a more accurate estimate of the actual concentration of pathogens than the results from agar-based cultures. However, treatment protocols should be based on the patient's clinical history, all associated laboratory test results, and the Guidelines from the Infectious Disease Society of America (IDSA) - Nicolle LE et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. Clin Infect Dis 2019 Mar 21; [e-pub]. (<https://doi.org/10.1093/cid/ciy1121>). This test was developed and its performance characteristics determined by Promus Diagnostics, LLC. It has not been cleared or approved by the FDA. However, such approval/clearance is not required, as the laboratory is regulated and qualified under CLIA to perform High - Complexity testing. This test is used for clinical purposes, and should not be regarded as investigational or for research.

The treatment guidance listed in the report is based upon infectious disease treatment references, the organisms detected, and genes known to contribute to medication resistance. Important clinical information such as comorbidities, renal function, patient weight, platelet count, microbiology results, etc. may influence the overall appropriateness of therapy. The provided guidance only takes drug allergies into account when they are provided and available to the pharmacist making the recommendation. The overall appropriateness of therapy must be determined by the physician treating the patient. The provider has all the information necessary to make that determination and should take the entire clinical presentation into account when making treatment decisions. Should the treating physician wish to discuss the provided guidance, the pharmacist is available for consult at the email and phone number provided.

This test was developed and its performance characteristics determined by Promus Diagnostics LLC. It has not been cleared or approved by the FDA. However, such approval/clearance is not required, as the laboratory is regulated and qualified under CLIA to perform high-complexity testing. This test is used for clinical purposes, and should not be regarded as investigational or for research.

Patient Information

Specimen Information

Facility Information

# SAMPLE REPORT #2

Facility Name:  
Provider Name:  
Address:

\*Antibiotic therapy is not indicated if pathogen(s) are detected at Low quantities. However, all clinical information should be considered when treatment decisions are made.

## Panel: Urinary Tract Infection (UTI) Panel, NAAT

Organism(s) Detected	Results	Semi-Quantitative (High / Medium / Low)	Est. Microbial Load* (CFU/mL)
Actinobaculum schaalii	Detected	Medium	10 <sup>4</sup> - 10 <sup>5</sup>
Aerococcus urinae	Detected	Medium	10 <sup>4</sup> - 10 <sup>5</sup>
Candida glabrata	Detected	Medium	10 <sup>4</sup> - 10 <sup>5</sup>
Viridans Group Strep	Detected	Low*	<10 <sup>4</sup>

## Panel: Antibiotic Resistance Genes

Resistance Gene(s) Detected	Antibiotic Class	Results
Sul1, Sul2	Sulfonamide (Sulfamethoxazole)	Sulfonamide Resistance Detected

### ANTIBIOTIC TREATMENT OPTIONS

**S** = Pathogen Detected is Sensitive to this Antibiotic Treatment

Medication	Actinobaculum schaalii	Aerococcus urinae	Candida glabrata	Viridans Group Strep
Amoxicillin	S	S		
Amoxicillin-Clavulanate				
Ampicillin				
Azithromycin				
Cefadroxil				
Cefdinir				
Cefixime				
Cefuroxime				
Cephalexin				
Cephalosporins				
Ciprofloxacin		S		
Clindamycin	S			S
Doxycycline				
Erythromycin				

Medication	Actinobaculum schaalii	Aerococcus urinae	Candida glabrata	Viridans Group Strep
Fluconazole			S	
Fosfomycin				
Levofloxacin				
Linezolid	S			S
Nitrofurantoin	S	S		
Ofloxacin				
Rifampin		S		
Sulfamethoxazole/Trimethoprim				
Tetracycline				
Trimethoprim/Sulfa				
Vancomycin	S	S		

Final Report Electronically signed by: Julia Bruggemann on 11/19/2022 at 03:28 PM

**Laboratory Director:** Dr. Nicole Massoll, M.D.



This test performed by Promus Diagnostics LLC, 2300 Dean Way, Suite 130, Southlake, TX 76092 CLIA#: 45D2156626; CAP#: 8412352

Please note: The semi-quantitative results for this test are based on estimates from internal validation studies performed at Promus Diagnostics and the scientific literature. These are intended to aid in guiding diagnostic and therapeutic decisions. Because of the increased sensitivity of PCR amplification used in this test compared to microbial culture, these results (genome copies / ml) may be a more accurate estimate of the actual concentration of pathogens than the results from agar-based cultures. However, treatment protocols should be based on the patient's clinical history, all associated laboratory test results, and the Guidelines from the Infectious Disease Society of America (IDSA) - Nicolle LE et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. Clin Infect Dis 2019 Mar 21; [e-pub]. (<https://doi.org/10.1093/cid/ciy1121>). This test was developed and its performance characteristics determined by Promus Diagnostics, LLC. It has not been cleared or approved by the FDA. However, such approval/clearance is not required, as the laboratory is regulated and qualified under CLIA to perform High - Complexity testing. This test is used for clinical purposes, and should not be regarded as investigational or for research.

The treatment guidance listed in the report is based upon infectious disease treatment references, the organisms detected, and genes known to contribute to medication resistance. Important clinical information such as comorbidities, renal function, patient weight, platelet count, microbiology results, etc. may influence the overall appropriateness of therapy. The provided guidance only takes drug allergies into account when they are provided and available to the pharmacist making the recommendation. The overall appropriateness of therapy must be determined by the physician treating the patient. The provider has all the information necessary to make that determination and should take the entire clinical presentation into account when making treatment decisions. Should the treating physician wish to discuss the provided guidance, the pharmacist is available for consult at the email and phone number provided.

Name: Lab Accession Number: D223230003 DOB: 1/4/1953

Report Date: 11/19/2022

## Tested Assay Results

### Panel: Urinary Tract Infection(UTI)

Organism	Results	Qualitative	Normal Reference Range
Acinetobacter baumannii	Not Detected	Negative	Not Detected
Candida albicans	Not Detected	Negative	Not Detected
Candida auris	Not Detected	Negative	Not Detected
Candida parapsilosis	Not Detected	Negative	Not Detected
Citrobacter freundii	Not Detected	Negative	Not Detected
Citrobacter koseri	Not Detected	Negative	Not Detected
Coagulase Negative Staph	Not Detected	Negative	Not Detected
Corynebacterium riegellii	Not Detected	Negative	Not Detected
Enterobacter aerogenes	Not Detected	Negative	Not Detected
Enterobacter cloacae	Not Detected	Negative	Not Detected
Enterococcus faecalis	Not Detected	Negative	Not Detected
Enterococcus faecium	Not Detected	Negative	Not Detected
Escherichia coli	Not Detected	Negative	Not Detected
Klebsiella oxytoca	Not Detected	Negative	Not Detected
Klebsiella pneumoniae	Not Detected	Negative	Not Detected
Morganella morganii	Not Detected	Negative	Not Detected
Mycoplasma hominis	Not Detected	Negative	Not Detected
Pantoea agglomerans	Not Detected	Negative	Not Detected
Proteus mirabilis	Not Detected	Negative	Not Detected
Proteus vulgaris	Not Detected	Negative	Not Detected
Providencia stuartii	Not Detected	Negative	Not Detected
Pseudomonas aeruginosa	Not Detected	Negative	Not Detected
Serratia marcescens	Not Detected	Negative	Not Detected
Staphylococcus aureus	Not Detected	Negative	Not Detected
Streptococcus agalactiae	Not Detected	Negative	Not Detected
Ureaplasma urealyticum	Not Detected	Negative	Not Detected
<b>Actinobaculum schaalii</b>	<b>Detected</b>	<b>Medium</b>	10 <sup>4</sup> - 10 <sup>5</sup>
<b>Aerococcus urinae</b>	<b>Detected</b>	<b>Medium</b>	10 <sup>4</sup> - 10 <sup>5</sup>
<b>Candida glabrata</b>	<b>Detected</b>	<b>Medium</b>	10 <sup>4</sup> - 10 <sup>5</sup>
<b>Viridans Group Strep</b>	<b>Detected</b>	<b>Low*</b>	<10 <sup>4</sup>

This test performed by Promus Diagnostics LLC, 2300 Dean Way, Suite 130, Southlake, TX 76092 CLIA#: 45D2156626; CAP#: 8412352

Please note: The semi-quantitative results for this test are based on estimates from internal validation studies performed at Promus Diagnostics and the scientific literature. These are intended to aid in guiding diagnostic and therapeutic decisions. Because of the increased sensitivity of PCR amplification used in this test compared to microbial culture, these results (genome copies / ml) may be a more accurate estimate of the actual concentration of pathogens than the results from agar-based cultures. However, treatment protocols should be based on the patients clinical history, all associated laboratory test results, and the Guidelines from the Infectious Disease Society of America (IDSA) - Nicolle LE et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. Clin Infect Dis 2019 Mar 21;[e-pub]. (<https://doi.org/10.1093/cid/ciy1121>). This test was developed and its performance characteristics determined by Promus Diagnostics, LLC. It has not been cleared or approved by the FDA. However, such approval/ clearance is not required, as the laboratory is regulated and qualified under CLIA to perform High - Complexity testing. This test is used for clinical purposes, and should not be regarded as investigational or for research

The treatment guidance listed in the report is based upon infectious disease treatment references, the organisms detected, and genes known to contribute to medication resistance. Important



clinical information such as comorbidities, renal function, patient weight, platelet count, microbiology results, etc. may influence the overall appropriateness of therapy. The provided guidance only takes drug allergies into account when they are provided and available to the pharmacist making the recommendation. The overall appropriateness of therapy must be determined by the physician treating the patient. The provider has all the information necessary to make that determination and should take the entire clinical presentation into account when making treatment decisions. Should the treating physician wish to discuss the provided guidance, the pharmacist is available for consult at the email and phone number provided.

This test was developed and its performance characteristics determined by Promus Diagnostics LLC. It has not been cleared or approved by the FDA. However, such approval/clearance is not required, as the laboratory is regulated and qualified under CLIA to perform high-complexity testing. This test is used for clinical purposes, and should not be regarded as investigational or for research.

Name: Lab Accession Number: D223230003 DOB: 1/4/1953

Report Date: 11/19/2022

# Tested Assay Results

## Panel: Antibiotic Resistance Genes

Resistance Gene(s)	Antibiotic Class	Results	Normal Reference Range
ACC	Beta-Lactamase - Class C Type	Not Detected	Not Detected
ampC	Beta-Lactamase - Class C Type	Not Detected	Not Detected
BIL/LAT/CMY	Beta-Lactamase - Class C Type	Not Detected	Not Detected
CTX-M group 1, CTX-M group 2, CTX-M group 9, CTX-M group 8/25	Beta-Lactamase - Class A Type	Not Detected	Not Detected
dfrA5, dfrA1	Trimethoprim	Not Detected	Not Detected
DHA	Beta-Lactamase - Class C Type	Not Detected	Not Detected
FOX	Beta-Lactamase - Class C Type	Not Detected	Not Detected
IMP-1 group, IMP-16, IMP-7	Beta-Lactamase - Class B Type	Not Detected	Not Detected
KPC	Beta-Lactamase - Class A Type	Not Detected	Not Detected
mecA	Methicillin	Not Detected	Not Detected
MOX/CMY	Beta-Lactamase - Class C Type	Not Detected	Not Detected
OXA-1, GES, PER-1, PER-2	Extended Spectrum BetaLactamase - Class A	Not Detected	Not Detected
OXA-23, OXA-72, OXA-40, blaOXA-48	Beta-Lactamase - Class D Type (Carbapenemase / Oxacillinase)	Not Detected	Not Detected
PER-1, PER-2	Extended Spectrum BetaLactamase - Class A	Not Detected	Not Detected
QnrA, QnrS, Qnr B	Fluoroquinolones	Not Detected	Not Detected
SHV	Beta-Lactamase - Class A Type	Not Detected	Not Detected
TEM	Beta-Lactamase - Class A Type	Not Detected	Not Detected
vanA1, vanA2, vanB	Vancomycin	Not Detected	Not Detected
VEB	Extended Spectrum BetaLactamase - Class A	Not Detected	Not Detected
VIM	Beta-Lactamase - Class B Type	Not Detected	Not Detected
<b>Sul1, Sul2</b>	<b>Sulfonamide (Sulfamethoxazole)</b>	<b>Detected</b>	Not Detected

This test performed by Promus Diagnostics LLC, 2300 Dean Way, Suite 130, Southlake, TX 76092 CLIA#: 45D2156626; CAP#: 8412352

Please note: The semi-quantitative results for this test are based on estimates from internal validation studies performed at Promus Diagnostics and the scientific literature. These are intended to aid in guiding diagnostic and therapeutic decisions. Because of the increased sensitivity of PCR amplification used in this test compared to microbial culture, these results (genome copies / ml) may be a more accurate estimate of the actual concentration of pathogens than the results from agar-based cultures. However, treatment protocols should be based on the patients clinical history, all associated laboratory test results, and the Guidelines from the Infectious Disease Society of America (IDSA) Nicole LE et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. Clin Infect Dis 2019 Mar 21; [e-pub]. (<https://doi.org/10.1093/cid/ciy1121>). This test was developed and its performance characteristics determined by Promus Diagnostics, LLC. It has not been cleared or approved by the FDA. However, such approval/ clearance is not required, as the laboratory is regulated and qualified under CLIA to perform High - Complexity testing. This test is used for clinical purposes, and should not be regarded as investigational or for research

The treatment guidance listed in the report is based upon infectious disease treatment references, the organisms detected, and genes known to contribute to medication resistance. Important clinical information such as comorbidities, renal function, patient weight, platelet count, microbiology results, etc. may influence the overall appropriateness of therapy. The provided guidance only takes drug allergies into account when they are provided and available to the pharmacist making the recommendation. The overall appropriateness of therapy must be determined by the physician treating the patient. The provider has all the information necessary to make that determination and should take the entire clinical presentation into account when making treatment decisions. Should the treating physician wish to discuss the provided guidance, the pharmacist is available for consult at the email and phone number provided.

This test was developed and its performance characteristics determined by Promus Diagnostics LLC. It has not been cleared or approved by the FDA. However, such approval/ clearance is not required, as the laboratory is regulated and qualified under CLIA to perform high-complexity testing. This test is used for clinical purposes, and should not be regarded as investigational or for research.

Patient Information

Specimen Information

Facility Information

# SAMPLE REPORT #3

Facility Name:  
Provider Name:  
Address:

\*Antibiotic therapy is not indicated if pathogen(s) are detected at Low quantities. However, all clinical information should be considered when treatment decisions are made.

## Panel: Urinary Tract Infection (UTI) Panel, NAAT

Organism(s) Detected	Results	Semi-Quantitative (High / Medium / Low)	Est. Microbial Load* (CFU/mL)
Ureaplasma urealyticum	Detected	Medium	10 <sup>4</sup> - 10 <sup>5</sup>
Candida albicans	Detected	Low*	<10 <sup>4</sup>

## Panel: Antibiotic Resistance Genes

Resistance Gene(s) Detected	Antibiotic Class	Results
No Antibiotic Resistance Genes Detected		

### ANTIBIOTIC TREATMENT OPTIONS

**S** = Pathogen Detected is Sensitive to this Antibiotic Treatment

Medication	Ureaplasma urealyticum	Candida albicans
Amoxicillin	<b>S</b>	
Amoxicillin-Clavulanate		
Ampicillin		
Azithromycin	<b>S</b>	
Cefadroxil		
Cefdinir		
Cefixime		
Cefuroxime		
Cephalexin		
Cephalosporins		
Ciprofloxacin		
Clindamycin		
Doxycycline		
Erythromycin		
Fluconazole		<b>S</b>
Fosfomycin		

Medication	Ureaplasma urealyticum	Candida albicans
Levofloxacin	S	
Linezolid		
Nitrofurantoin		
Ofloxacin	S	
Rifampin		
Sulfamethoxazole/Trimethoprim		
Tetracycline		
Trimethoprim/Sulfa		
Vancomycin		

Final Report Electronically signed by: Julia Bruggemann on 11/19/2022 at 03:25 PM

**Laboratory Director:** Dr. Nicole Massoll, M.D.



This test performed by Promus Diagnostics LLC, 2300 Dean Way, Suite 130, Southlake, TX 76092 CLIA#: 45D2156626; CAP#: 8412352

Please note: The semi-quantitative results for this test are based on estimates from internal validation studies performed at Promus Diagnostics and the scientific literature. These are intended to aid in guiding diagnostic and therapeutic decisions. Because of the increased sensitivity of PCR amplification used in this test compared to microbial culture, these results (genome copies / ml) may be a more accurate estimate of the actual concentration of pathogens than the results from agar-based cultures. However, treatment protocols should be based on the patient's clinical history, all associated laboratory test results, and the Guidelines from the Infectious Disease Society of America (IDSA) - Nicolle LE et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. Clin Infect Dis 2019 Mar 21; [e-pub]. (<https://doi.org/10.1093/cid/ciy1121>). This test was developed and its performance characteristics determined by Promus Diagnostics, LLC. It has not been cleared or approved by the FDA. However, such approval/clearance is not required, as the laboratory is regulated and qualified under CLIA to perform High - Complexity testing. This test is used for clinical purposes, and should not be regarded as investigational or for research.

The treatment guidance listed in the report is based upon infectious disease treatment references, the organisms detected, and genes known to contribute to medication resistance. Important clinical information such as comorbidities, renal function, patient weight, platelet count, microbiology results, etc. may influence the overall appropriateness of therapy. The provided guidance only takes drug allergies into account when they are provided and available to the pharmacist making the recommendation. The overall appropriateness of therapy must be determined by the physician treating the patient. The provider has all the information necessary to make that determination and should take the entire clinical presentation into account when making treatment decisions. Should the treating physician wish to discuss the provided guidance, the pharmacist is available for consult at the email and phone number provided.

Name: Lab Accession Number: D223230008 DOB: 2/11/1995

Report Date: 11/19/2022

## Tested Assay Results

### Panel: Urinary Tract Infection(UTI)

Organism	Results	Qualitative	Normal Reference Range
Acinetobacter baumannii	Not Detected	Negative	Not Detected
Actinobaculum schaalii	Not Detected	Negative	Not Detected
Aerococcus urinae	Not Detected	Negative	Not Detected
Candida auris	Not Detected	Negative	Not Detected
Candida glabrata	Not Detected	Negative	Not Detected
Candida parapsilosis	Not Detected	Negative	Not Detected
Citrobacter freundii	Not Detected	Negative	Not Detected
Citrobacter koseri	Not Detected	Negative	Not Detected
Coagulase Negative Staph	Not Detected	Negative	Not Detected
Corynebacterium riegelii	Not Detected	Negative	Not Detected
Enterobacter aerogenes	Not Detected	Negative	Not Detected
Enterobacter cloacae	Not Detected	Negative	Not Detected
Enterococcus faecalis	Not Detected	Negative	Not Detected
Enterococcus faecium	Not Detected	Negative	Not Detected
Escherichia coli	Not Detected	Negative	Not Detected
Klebsiella oxytoca	Not Detected	Negative	Not Detected
Klebsiella pneumoniae	Not Detected	Negative	Not Detected
Morganella morganii	Not Detected	Negative	Not Detected
Mycoplasma hominis	Not Detected	Negative	Not Detected
Pantoea agglomerans	Not Detected	Negative	Not Detected
Proteus mirabilis	Not Detected	Negative	Not Detected
Proteus vulgaris	Not Detected	Negative	Not Detected
Providencia stuartii	Not Detected	Negative	Not Detected
Pseudomonas aeruginosa	Not Detected	Negative	Not Detected
Serratia marcescens	Not Detected	Negative	Not Detected
Staphylococcus aureus	Not Detected	Negative	Not Detected
Streptococcus agalactiae	Not Detected	Negative	Not Detected
Viridans Group Strep	Not Detected	Negative	Not Detected
<b>Ureaplasma urealyticum</b>	<b>Detected</b>	<b>Medium</b>	10 <sup>4</sup> - 10 <sup>5</sup>
<b>Candida albicans</b>	<b>Detected</b>	<b>Low*</b>	<10 <sup>4</sup>

This test performed by Promus Diagnostics LLC, 2300 Dean Way, Suite 130, Southlake, TX 76092 CLIA#: 45D2156626; CAP#: 8412352

Please note: The semi-quantitative results for this test are based on estimates from internal validation studies performed at Promus Diagnostics and the scientific literature. These are intended to aid in guiding diagnostic and therapeutic decisions. Because of the increased sensitivity of PCR amplification used in this test compared to microbial culture, these results (genome copies / ml) may be a more accurate estimate of the actual concentration of pathogens than the results from agar-based cultures. However, treatment protocols should be based on the patients clinical history, all associated laboratory test results, and the Guidelines from the Infectious Disease Society of America (IDSA) Nicolle LE et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. Clin Infect Dis 2019 Mar 21;[e-pub]. (<https://doi.org/10.1093/cid/ciy1121>). This test was developed and its performance characteristics determined by Promus Diagnostics, LLC. It has not been cleared or approved by the FDA. However, such approval/ clearance is not required, as the laboratory is regulated and qualified under CLIA to perform High - Complexity testing. This test is used for clinical purposes, and should not be regarded as investigational or for research

The treatment guidance listed in the report is based upon infectious disease treatment references, the organisms detected, and genes known to contribute to medication resistance. Important

clinical information such as comorbidities, renal function, patient weight, platelet count, microbiology results, etc. may influence the overall appropriateness of therapy. The provided guidance only takes drug allergies into account when they are provided and available to the pharmacist making the recommendation. The overall appropriateness of therapy must be determined by the physician treating the patient. The provider has all the information necessary to make that determination and should take the entire clinical presentation into account when making treatment decisions. Should the treating physician wish to discuss the provided guidance, the pharmacist is available for consult at the email and phone number provided.

This test was developed and its performance characteristics determined by Promus Diagnostics LLC. It has not been cleared or approved by the FDA. However, such approval/clearance is not required, as the laboratory is regulated and qualified under CLIA to perform high-complexity testing. This test is used for clinical purposes, and should not be regarded as investigational or for research.

Name: Lab Accession Number: D223230008 DOB: 2/11/1995

Report Date: 11/19/2022

## Tested Assay Results

### Panel: Antibiotic Resistance Genes

Resistance Gene(s)	Antibiotic Class	Results	Normal Reference Range
ACC	Beta-Lactamase - Class C Type	Not Detected	Not Detected
ampC	Beta-Lactamase - Class C Type	Not Detected	Not Detected
BIL/LAT/CMY	Beta-Lactamase - Class C Type	Not Detected	Not Detected
CTX-M group 1, CTX-M group 2, CTX-M group 9, CTX-M group 8/25	Beta-Lactamase - Class A Type	Not Detected	Not Detected
dfrA5, dfrA1	Trimethoprim	Not Detected	Not Detected
DHA	Beta-Lactamase - Class C Type	Not Detected	Not Detected
FOX	Beta-Lactamase - Class C Type	Not Detected	Not Detected
IMP-1 group, IMP-16, IMP-7	Beta-Lactamase - Class B Type	Not Detected	Not Detected
KPC	Beta-Lactamase - Class A Type	Not Detected	Not Detected
MOX/CMY	Beta-Lactamase - Class C Type	Not Detected	Not Detected
OXA-1, GES, PER-1, PER-2	Extended Spectrum BetaLactamase - Class A	Not Detected	Not Detected
OXA-23, OXA-72, OXA-40, blaOXA-48	Beta-Lactamase - Class D Type (Carbapenemase / Oxacillinase)	Not Detected	Not Detected
PER-1, PER-2	Extended Spectrum BetaLactamase - Class A	Not Detected	Not Detected
QnrA, QnrS, Qnr B	Fluoroquinolones	Not Detected	Not Detected
SHV	Beta-Lactamase - Class A Type	Not Detected	Not Detected
Sul1, Sul2	Sulfonamide (Sulfamethoxazole)	Not Detected	Not Detected
TEM	Beta-Lactamase - Class A Type	Not Detected	Not Detected
vanA1, vanA2, vanB	Vancomycin	Not Detected	Not Detected
VEB	Extended Spectrum BetaLactamase - Class A	Not Detected	Not Detected
VIM	Beta-Lactamase - Class B Type	Not Detected	Not Detected
mecA	Methicillin	Not Detected	Not Detected

This test performed by Promus Diagnostics LLC, 2300 Dean Way, Suite 130, Southlake, TX 76092 CLIA#: 45D2156626; CAP#: 8412352

Please note: The semi-quantitative results for this test are based on estimates from internal validation studies performed at Promus Diagnostics and the scientific literature. These are intended to aid in guiding diagnostic and therapeutic decisions. Because of the increased sensitivity of PCR amplification used in this test compared to microbial culture, these results (genome copies / ml) may be a more accurate estimate of the actual concentration of pathogens than the results from agar-based cultures. However, treatment protocols should be based on the patients clinical history, all associated laboratory test results, and the Guidelines from the Infectious Disease Society of America (IDSA) Nicolle LE et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. Clin Infect Dis 2019 Mar 21; [e-pub]. (<https://doi.org/10.1093/cid/ciy1121>). This test was developed and its performance characteristics determined by Promus Diagnostics, LLC. It has not been cleared or approved by the FDA. However, such approval/ clearance is not required, as the laboratory is regulated and qualified under CLIA to perform High - Complexity testing. This test is used for clinical purposes, and should not be regarded as investigational or for research

The treatment guidance listed in the report is based upon infectious disease treatment references, the organisms detected, and genes known to contribute to medication resistance. Important clinical information such as comorbidities, renal function, patient weight, platelet count, microbiology results, etc. may influence the overall appropriateness of therapy. The provided guidance only takes drug allergies into account when they are provided and available to the pharmacist making the recommendation. The overall appropriateness of therapy must be determined by the physician treating the patient. The provider has all the information necessary to make that determination and should take the entire clinical presentation into account when making treatment decisions. Should the treating physician wish to discuss the provided guidance, the pharmacist is available for consult at the email and phone number provided.

This test was developed and its performance characteristics determined by Promus Diagnostics LLC. It has not been cleared or approved by the FDA. However, such approval/clearance is not required, as the laboratory is regulated and qualified under CLIA to perform high-complexity testing. This test is used for clinical purposes, and should not be regarded as investigational or for research.

Patient Information

Specimen Information

Facility Information

Facility Name:

Provider Name:

Address:

# SAMPLE REPORT #4

\*Antibiotic therapy is not indicated if pathogen(s) are detected at Low quantities. However, all clinical information should be considered when treatment decisions are made.

## Panel: Urinary Tract Infection (UTI) Panel, NAAT

Organism(s) Detected	Results	Semi-Quantitative (High / Medium / Low)	Est. Microbial Load* (CFU/mL)
Coagulase Negative Staph	<b>Detected</b>	<b>Low*</b>	<10 <sup>4</sup>

## Panel: Antibiotic Resistance Genes

Resistance Gene(s) Detected	Antibiotic Class	Results
mecA	Methicillin	Methicillin Resistance Detected

### ANTIBIOTIC TREATMENT OPTIONS

**S** = Pathogen Detected is Sensitive to this Antibiotic Treatment

Medication	Coagulase Negative Staph
Amoxicillin	
Amoxicillin-Clavulanate	
Ampicillin	
Azithromycin	
Cefadroxil	
Cefdinir	
Cefixime	
Cefuroxime	
Cephalexin	
Cephalosporins	
Ciprofloxacin	<b>S</b>
Clindamycin	
Doxycycline	
Erythromycin	
Fluconazole	
Fosfomycin	
Levofloxacin	



Medication	Coagulase Negative Staph
Linezolid	
Nitrofurantoin	<b>S</b>
Ofloxacin	
Rifampin	
Sulfamethoxazole/Trimethoprim	<b>S</b>
Tetracycline	
Trimethoprim/Sulfa	
Vancomycin	<b>S</b>

Final Report Electronically signed by: Julia Bruggemann on 11/19/2022 at 01:51 PM

**Laboratory Director:** Dr. Nicole Massoll, M.D.



This test performed by Promus Diagnostics LLC, 2300 Dean Way, Suite 130, Southlake, TX 76092 CLIA#: 45D2156626; CAP#: 8412352

Please note: The semi-quantitative results for this test are based on estimates from internal validation studies performed at Promus Diagnostics and the scientific literature. These are intended to aid in guiding diagnostic and therapeutic decisions. Because of the increased sensitivity of PCR amplification used in this test compared to microbial culture, these results (genome copies / ml) may be a more accurate estimate of the actual concentration of pathogens than the results from agar-based cultures. However, treatment protocols should be based on the patient's clinical history, all associated laboratory test results, and the Guidelines from the Infectious Disease Society of America (IDSA) - Nicolle LE et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. Clin Infect Dis 2019 Mar 21;[e-pub]. (<https://doi.org/10.1093/cid/ciy1121>). This test was developed and its performance characteristics determined by Promus Diagnostics, LLC. It has not been cleared or approved by the FDA. However, such approval/clearance is not required, as the laboratory is regulated and qualified under CLIA to perform High - Complexity testing. This test is used for clinical purposes, and should not be regarded as investigational or for research.

The treatment guidance listed in the report is based upon infectious disease treatment references, the organisms detected, and genes known to contribute to medication resistance. Important clinical information such as comorbidities, renal function, patient weight, platelet count, microbiology results, etc. may influence the overall appropriateness of therapy. The provided guidance only takes drug allergies into account when they are provided and available to the pharmacist making the recommendation. The overall appropriateness of therapy must be determined by the physician treating the patient. The provider has all the information necessary to make that determination and should take the entire clinical presentation into account when making treatment decisions. Should the treating physician wish to discuss the provided guidance, the pharmacist is available for consult at the email and phone number provided.

Name: Lab Accession Number: D223220068 DOB: 4/16/1956

Report Date: 11/19/2022

## Tested Assay Results

### Panel: Urinary Tract Infection(UTI)

Organism	Results	Qualitative	Normal Reference Range
Acinetobacter baumannii	Not Detected	Negative	Not Detected
Actinobaculum schaalii	Not Detected	Negative	Not Detected
Aerococcus urinae	Not Detected	Negative	Not Detected
Candida albicans	Not Detected	Negative	Not Detected
Candida auris	Not Detected	Negative	Not Detected
Candida glabrata	Not Detected	Negative	Not Detected
Candida parapsilosis	Not Detected	Negative	Not Detected
Citrobacter freundii	Not Detected	Negative	Not Detected
Citrobacter koseri	Not Detected	Negative	Not Detected
Corynebacterium riegelii	Not Detected	Negative	Not Detected
Enterobacter aerogenes	Not Detected	Negative	Not Detected
Enterobacter cloacae	Not Detected	Negative	Not Detected
Enterococcus faecalis	Not Detected	Negative	Not Detected
Enterococcus faecium	Not Detected	Negative	Not Detected
Escherichia coli	Not Detected	Negative	Not Detected
Klebsiella oxytoca	Not Detected	Negative	Not Detected
Klebsiella pneumoniae	Not Detected	Negative	Not Detected
Morganella morganii	Not Detected	Negative	Not Detected
Mycoplasma hominis	Not Detected	Negative	Not Detected
Pantoea agglomerans	Not Detected	Negative	Not Detected
Proteus mirabilis	Not Detected	Negative	Not Detected
Proteus vulgaris	Not Detected	Negative	Not Detected
Providencia stuartii	Not Detected	Negative	Not Detected
Pseudomonas aeruginosa	Not Detected	Negative	Not Detected
Serratia marcescens	Not Detected	Negative	Not Detected
Staphylococcus aureus	Not Detected	Negative	Not Detected
Streptococcus agalactiae	Not Detected	Negative	Not Detected
Ureaplasma urealyticum	Not Detected	Negative	Not Detected
Viridans Group Strep	Not Detected	Negative	Not Detected
<b>Coagulase Negative Staph</b>	<b>Detected</b>	<b>Low*</b>	<b>&lt;10<sup>4</sup></b>

This test performed by Promus Diagnostics LLC, 2300 Dean Way, Suite 130, Southlake, TX 76092 CLIA#: 45D2156626; CAP#: 8412352

Please note: The semi-quantitative results for this test are based on estimates from internal validation studies performed at Promus Diagnostics and the scientific literature. These are intended to aid in guiding diagnostic and therapeutic decisions. Because of the increased sensitivity of PCR amplification used in this test compared to microbial culture, these results (genome copies / ml) may be a more accurate estimate of the actual concentration of pathogens than the results from agar-based cultures. However, treatment protocols should be based on the patients clinical history, all associated laboratory test results, and the Guidelines from the Infectious Disease Society of America (IDSA) Nicolle LE et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. Clin Infect Dis 2019 Mar 21; [e-pub]. (<https://doi.org/10.1093/cid/cjy1121>). This test was developed and its performance characteristics determined by Promus Diagnostics, LLC. It has not been cleared or approved by the FDA. However, such approval/ clearance is not required, as the laboratory is regulated and qualified under CLIA to perform High - Complexity testing. This test is used for clinical purposes, and should not be regarded as investigational or for research

The treatment guidance listed in the report is based upon infectious disease treatment references, the organisms detected, and genes known to contribute to medication resistance. Important clinical information such as comorbidities, renal function, patient weight, platelet count, microbiology results, etc. may influence the overall appropriateness of therapy. The provided guidance

only takes drug allergies into account when they are provided and available to the pharmacist making the recommendation. The overall appropriateness of therapy must be determined by the physician treating the patient. The provider has all the information necessary to make that determination and should take the entire clinical presentation into account when making treatment decisions. Should the treating physician wish to discuss the provided guidance, the pharmacist is available for consult at the email and phone number provided.

This test was developed and its performance characteristics determined by Promus Diagnostics LLC. It has not been cleared or approved by the FDA. However, such approval/clearance is not required, as the laboratory is regulated and qualified under CLIA to perform high-complexity testing. This test is used for clinical purposes, and should not be regarded as investigational or for research.

Name: Lab Accession Number: D223220068 DOB: 4/16/1956

Report Date: 11/19/2022

## Tested Assay Results

### Panel: Antibiotic Resistance Genes

Resistance Gene(s)	Antibiotic Class	Results	Normal Reference Range
ACC	Beta-Lactamase - Class C Type	Not Detected	Not Detected
ampC	Beta-Lactamase - Class C Type	Not Detected	Not Detected
BIL/LAT/CMY	Beta-Lactamase - Class C Type	Not Detected	Not Detected
CTX-M group 1, CTX-M group 2, CTX-M group 9, CTX-M group 8/25	Beta-Lactamase - Class A Type	Not Detected	Not Detected
dfrA5, dfrA1	Trimethoprim	Not Detected	Not Detected
DHA	Beta-Lactamase - Class C Type	Not Detected	Not Detected
FOX	Beta-Lactamase - Class C Type	Not Detected	Not Detected
IMP-1 group, IMP-16, IMP-7	Beta-Lactamase - Class B Type	Not Detected	Not Detected
KPC	Beta-Lactamase - Class A Type	Not Detected	Not Detected
MOX/CMY	Beta-Lactamase - Class C Type	Not Detected	Not Detected
OXA-1, GES, PER-1, PER-2	Extended Spectrum BetaLactamase - Class A	Not Detected	Not Detected
OXA-23, OXA-72, OXA-40, blaOXA-48	Beta-Lactamase - Class D Type (Carbapenemase / Oxacillinase)	Not Detected	Not Detected
PER-1, PER-2	Extended Spectrum BetaLactamase - Class A	Not Detected	Not Detected
QnrA, QnrS, Qnr B	Fluoroquinolones	Not Detected	Not Detected
SHV	Beta-Lactamase - Class A Type	Not Detected	Not Detected
Sul1, Sul2	Sulfonamide (Sulfamethoxazole)	Not Detected	Not Detected
TEM	Beta-Lactamase - Class A Type	Not Detected	Not Detected
vanA1, vanA2, vanB	Vancomycin	Not Detected	Not Detected
VEB	Extended Spectrum BetaLactamase - Class A	Not Detected	Not Detected
VIM	Beta-Lactamase - Class B Type	Not Detected	Not Detected
<b>mecA</b>	<b>Methicillin</b>	<b>Detected</b>	Not Detected

This test performed by Promus Diagnostics LLC, 2300 Dean Way, Suite 130, Southlake, TX 76092 CLIA#: 45D2156626; CAP#: 8412352

Please note: The semi-quantitative results for this test are based on estimates from internal validation studies performed at Promus Diagnostics and the scientific literature. These are intended to aid in guiding diagnostic and therapeutic decisions. Because of the increased sensitivity of PCR amplification used in this test compared to microbial culture, these results (genome copies / ml) may be a more accurate estimate of the actual concentration of pathogens than the results from agar-based cultures. However, treatment protocols should be based on the patients clinical history, all associated laboratory test results, and the Guidelines from the Infectious Disease Society of America (IDSA) Nicole LE et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. Clin Infect Dis 2019 Mar 21; [e-pub]. (<https://doi.org/10.1093/cid/ciy1121>). This test was developed and its performance characteristics determined by Promus Diagnostics, LLC. It has not been cleared or approved by the FDA. However, such approval/ clearance is not required, as the laboratory is regulated and qualified under CLIA to perform High - Complexity testing. This test is used for clinical purposes, and should not be regarded as investigational or for research

The treatment guidance listed in the report is based upon infectious disease treatment references, the organisms detected, and genes known to contribute to medication resistance. Important clinical information such as comorbidities, renal function, patient weight, platelet count, microbiology results, etc. may influence the overall appropriateness of therapy. The provided guidance only takes drug allergies into account when they are provided and available to the pharmacist making the recommendation. The overall appropriateness of therapy must be determined by the physician treating the patient. The provider has all the information necessary to make that determination and should take the entire clinical presentation into account when making treatment decisions. Should the treating physician wish to discuss the provided guidance, the pharmacist is available for consult at the email and phone number provided.

This test was developed and its performance characteristics determined by Promus Diagnostics LLC. It has not been cleared or approved by the FDA. However, such approval/ clearance is not required, as the laboratory is regulated and qualified under CLIA to perform high-complexity testing. This test is used for clinical purposes, and should not be regarded as investigational or for research.

Patient Information

Specimen Information

Facility Information

Facility Name:  
Provider Name:  
Address:

# SAMPLE REPORT #5

\*Antibiotic therapy is not indicated if pathogen(s) are detected at Low quantities. However, all clinical information should be considered when treatment decisions are made.

## Panel: Urinary Tract Infection (UTI) Panel, NAAT

Organism(s) Detected	Results	Semi-Quantitative (High / Medium / Low)	Est. Microbial Load* (CFU/mL)
Escherichia coli	Detected	High	>10 <sup>5</sup>

## Panel: Antibiotic Resistance Genes

Resistance Gene(s) Detected	Antibiotic Class	Results
Sul1, Sul2	Sulfonamide (Sulfamethoxazole)	Sulfonamide Resistance Detected
TEM	Beta-Lactamase - Class A Type	Beta Lactam Resistance Detected

### ANTIBIOTIC TREATMENT OPTIONS

**S** = Pathogen Detected is Sensitive to this Antibiotic Treatment

Medication	Escherichia coli
Amoxicillin	
Amoxicillin-Clavulanate	
Ampicillin	
Azithromycin	
Cefadroxil	
Cefdinir	
Cefixime	
Cefuroxime	
Cephalexin	
Cephalosporins	
Ciprofloxacin	
Clindamycin	
Doxycycline	
Erythromycin	
Fluconazole	
Fosfomycin	<b>S</b>

Medication	Escherichia coli
Levofloxacin	
Linezolid	
Nitrofurantoin	<b>S</b>
Ofloxacin	
Rifampin	
Sulfamethoxazole/Trimethoprim	
Tetracycline	
Trimethoprim/Sulfa	
Vancomycin	

Final Report Electronically signed by: Julia Bruggemann on 11/19/2022 at 03:29 PM

**Laboratory Director:** Dr. Nicole Massoll, M.D.



This test performed by Promus Diagnostics LLC, 2300 Dean Way, Suite 130, Southlake, TX 76092 CLIA#: 45D2156626; CAP#: 8412352

Please note: The semi-quantitative results for this test are based on estimates from internal validation studies performed at Promus Diagnostics and the scientific literature. These are intended to aid in guiding diagnostic and therapeutic decisions. Because of the increased sensitivity of PCR amplification used in this test compared to microbial culture, these results (genome copies / ml) may be a more accurate estimate of the actual concentration of pathogens than the results from agar-based cultures. However, treatment protocols should be based on the patient's clinical history, all associated laboratory test results, and the Guidelines from the Infectious Disease Society of America (IDSA) - Nicole LE et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. Clin Infect Dis 2019 Mar 21; [e-pub]. (<https://doi.org/10.1093/cid/ciy1121>). This test was developed and its performance characteristics determined by Promus Diagnostics, LLC. It has not been cleared or approved by the FDA. However, such approval/clearance is not required, as the laboratory is regulated and qualified under CLIA to perform High - Complexity testing. This test is used for clinical purposes, and should not be regarded as investigational or for research.

The treatment guidance listed in the report is based upon infectious disease treatment references, the organisms detected, and genes known to contribute to medication resistance. Important clinical information such as comorbidities, renal function, patient weight, platelet count, microbiology results, etc. may influence the overall appropriateness of therapy. The provided guidance only takes drug allergies into account when they are provided and available to the pharmacist making the recommendation. The overall appropriateness of therapy must be determined by the physician treating the patient. The provider has all the information necessary to make that determination and should take the entire clinical presentation into account when making treatment decisions. Should the treating physician wish to discuss the provided guidance, the pharmacist is available for consult at the email and phone number provided.

Name: Lab Accession Number: D223230002 DOB: 5/28/1961

Report Date: 11/19/2022

## Tested Assay Results

### Panel: Urinary Tract Infection(UTI)

Organism	Results	Qualitative	Normal Reference Range
Acinetobacter baumannii	Not Detected	Negative	Not Detected
Actinobaculum schaalii	Not Detected	Negative	Not Detected
Aerococcus urinae	Not Detected	Negative	Not Detected
Candida albicans	Not Detected	Negative	Not Detected
Candida auris	Not Detected	Negative	Not Detected
Candida glabrata	Not Detected	Negative	Not Detected
Candida parapsilosis	Not Detected	Negative	Not Detected
Citrobacter freundii	Not Detected	Negative	Not Detected
Citrobacter koseri	Not Detected	Negative	Not Detected
Coagulase Negative Staph	Not Detected	Negative	Not Detected
Corynebacterium riegelii	Not Detected	Negative	Not Detected
Enterobacter aerogenes	Not Detected	Negative	Not Detected
Enterobacter cloacae	Not Detected	Negative	Not Detected
Enterococcus faecalis	Not Detected	Negative	Not Detected
Enterococcus faecium	Not Detected	Negative	Not Detected
Klebsiella oxytoca	Not Detected	Negative	Not Detected
Klebsiella pneumoniae	Not Detected	Negative	Not Detected
Morganella morganii	Not Detected	Negative	Not Detected
Mycoplasma hominis	Not Detected	Negative	Not Detected
Pantoea agglomerans	Not Detected	Negative	Not Detected
Proteus mirabilis	Not Detected	Negative	Not Detected
Proteus vulgaris	Not Detected	Negative	Not Detected
Providencia stuartii	Not Detected	Negative	Not Detected
Pseudomonas aeruginosa	Not Detected	Negative	Not Detected
Serratia marcescens	Not Detected	Negative	Not Detected
Staphylococcus aureus	Not Detected	Negative	Not Detected
Streptococcus agalactiae	Not Detected	Negative	Not Detected
Ureaplasma urealyticum	Not Detected	Negative	Not Detected
Viridans Group Strep	Not Detected	Negative	Not Detected
<b>Escherichia coli</b>	<b>Detected</b>	<b>High</b>	>10 <sup>5</sup>

This test performed by Promus Diagnostics LLC, 2300 Dean Way, Suite 130, Southlake, TX 76092 CLIA#: 45D2156626; CAP#: 8412352

Please note: The semi-quantitative results for this test are based on estimates from internal validation studies performed at Promus Diagnostics and the scientific literature. These are intended to aid in guiding diagnostic and therapeutic decisions. Because of the increased sensitivity of PCR amplification used in this test compared to microbial culture, these results (genome copies / ml) may be a more accurate estimate of the actual concentration of pathogens than the results from agar-based cultures. However, treatment protocols should be based on the patients clinical history, all associated laboratory test results, and the Guidelines from the Infectious Disease Society of America (IDSA) Nicolle LE et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. Clin Infect Dis 2019 Mar 21; [e-pub]. (<https://doi.org/10.1093/cid/ciy1121>). This test was developed and its performance characteristics determined by Promus Diagnostics, LLC. It has not been cleared or approved by the FDA. However, such approval/ clearance is not required, as the laboratory is regulated and qualified under CLIA to perform High - Complexity testing. This test is used for clinical purposes, and should not be regarded as investigational or for research

The treatment guidance listed in the report is based upon infectious disease treatment references, the organisms detected, and genes known to contribute to medication resistance. Important clinical information such as comorbidities, renal function, patient weight, platelet count, microbiology results, etc. may influence the overall appropriateness of therapy. The provided guidance

only takes drug allergies into account when they are provided and available to the pharmacist making the recommendation. The overall appropriateness of therapy must be determined by the physician treating the patient. The provider has all the information necessary to make that determination and should take the entire clinical presentation into account when making treatment decisions. Should the treating physician wish to discuss the provided guidance, the pharmacist is available for consult at the email and phone number provided.

This test was developed and its performance characteristics determined by Promus Diagnostics LLC. It has not been cleared or approved by the FDA. However, such approval/clearance is not required, as the laboratory is regulated and qualified under CLIA to perform high-complexity testing. This test is used for clinical purposes, and should not be regarded as investigational or for research.



Name: Lab Accession Number: D223230002 DOB: 5/28/1961

Report Date: 11/19/2022

## Tested Assay Results

### Panel: Antibiotic Resistance Genes

Resistance Gene(s)	Antibiotic Class	Results	Normal Reference Range
ACC	Beta-Lactamase - Class C Type	Not Detected	Not Detected
ampC	Beta-Lactamase - Class C Type	Not Detected	Not Detected
BIL/LAT/CMY	Beta-Lactamase - Class C Type	Not Detected	Not Detected
CTX-M group 1, CTX-M group 2, CTX-M group 9, CTX-M group 8/25	Beta-Lactamase - Class A Type	Not Detected	Not Detected
dfrA5, dfrA1	Trimethoprim	Not Detected	Not Detected
DHA	Beta-Lactamase - Class C Type	Not Detected	Not Detected
FOX	Beta-Lactamase - Class C Type	Not Detected	Not Detected
IMP-1 group, IMP-16, IMP-7	Beta-Lactamase - Class B Type	Not Detected	Not Detected
KPC	Beta-Lactamase - Class A Type	Not Detected	Not Detected
mecA	Methicillin	Not Detected	Not Detected
MOX/CMY	Beta-Lactamase - Class C Type	Not Detected	Not Detected
OXA-1, GES, PER-1, PER-2	Extended Spectrum BetaLactamase - Class A	Not Detected	Not Detected
OXA-23, OXA-72, OXA-40, blaOXA-48	Beta-Lactamase - Class D Type (Carbapenemase / Oxacillinase)	Not Detected	Not Detected
PER-1, PER-2	Extended Spectrum BetaLactamase - Class A	Not Detected	Not Detected
QnrA, QnrS, Qnr B	Fluoroquinolones	Not Detected	Not Detected
SHV	Beta-Lactamase - Class A Type	Not Detected	Not Detected
vanA1, vanA2, vanB	Vancomycin	Not Detected	Not Detected
VEB	Extended Spectrum BetaLactamase - Class A	Not Detected	Not Detected
VIM	Beta-Lactamase - Class B Type	Not Detected	Not Detected
<b>Sul1, Sul2</b>	<b>Sulfonamide (Sulfamethoxazole)</b>	<b>Detected</b>	Not Detected
<b>TEM</b>	<b>Beta-Lactamase - Class A Type</b>	<b>Detected</b>	Not Detected

This test performed by Promus Diagnostics LLC, 2300 Dean Way, Suite 130, Southlake, TX 76092 CLIA#: 45D2156626; CAP#: 8412352

Please note: The semi-quantitative results for this test are based on estimates from internal validation studies performed at Promus Diagnostics and the scientific literature. These are intended to aid in guiding diagnostic and therapeutic decisions. Because of the increased sensitivity of PCR amplification used in this test compared to microbial culture, these results (genome copies / ml) may be a more accurate estimate of the actual concentration of pathogens than the results from agar-based cultures. However, treatment protocols should be based on the patients clinical history, all associated laboratory test results, and the Guidelines from the Infectious Disease Society of America (IDSA) Nicole LE et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. Clin Infect Dis 2019 Mar 21;[e-pub]. (<https://doi.org/10.1093/cid/ciy1121>). This test was developed and its performance characteristics determined by Promus Diagnostics, LLC. It has not been cleared or approved by the FDA. However, such approval/ clearance is not required, as the laboratory is regulated and qualified under CLIA to perform High - Complexity testing. This test is used for clinical purposes, and should not be regarded as investigational or for research

The treatment guidance listed in the report is based upon infectious disease treatment references, the organisms detected, and genes known to contribute to medication resistance. Important clinical information such as comorbidities, renal function, patient weight, platelet count, microbiology results, etc. may influence the overall appropriateness of therapy. The provided guidance only takes drug allergies into account when they are provided and available to the pharmacist making the recommendation. The overall appropriateness of therapy must be determined by the physician treating the patient. The provider has all the information necessary to make that determination and should take the entire clinical presentation into account when making treatment decisions. Should the treating physician wish to discuss the provided guidance, the pharmacist is available for consult at the email and phone number provided.

This test was developed and its performance characteristics determined by Promus Diagnostics LLC. It has not been cleared or approved by the FDA. However, such approval/clearance is not required, as the laboratory is regulated and qualified under CLIA to perform high-complexity testing. This test is used for clinical purposes, and should not be regarded as investigational or for research.

Patient Information

Specimen Information

Facility Information

# SAMPLE REPORT #6

Facility Name:  
Provider Name:  
Address:

\*Antibiotic therapy is not indicated if pathogen(s) are detected at Low quantities. However, all clinical information should be considered when treatment decisions are made.

## Panel: Urinary Tract Infection (UTI) Panel, NAAT

Organism(s) Detected	Results	Semi-Quantitative (High / Medium / Low)	Est. Microbial Load* (CFU/mL)
Viridans Group Strep	Detected	Medium	10 <sup>4</sup> - 10 <sup>5</sup>
Coagulase Negative Staph	Detected	Low*	<10 <sup>4</sup>
Escherichia coli	Detected	Low*	<10 <sup>4</sup>

## Panel: Antibiotic Resistance Genes

Resistance Gene(s) Detected	Antibiotic Class	Results
dfrA5, dfrA1	Trimethoprim	Trimethoprim Resistance Detected
mecA	Methicillin	Methicillin Resistance Detected
Sul1, Sul2	Sulfonamide (Sulfamethoxazole)	Sulfonamide Resistance Detected
TEM	Beta-Lactamase - Class A Type	Beta Lactam Resistance Detected

### ANTIBIOTIC TREATMENT OPTIONS

**S** = Pathogen Detected is Sensitive to this Antibiotic Treatment

Medication	Viridans Group Strep	Coagulase Negative Staph	Escherichia coli
Amoxicillin			
Amoxicillin-Clavulanate			
Ampicillin			
Azithromycin			
Cefadroxil			
Cefdinir			
Cefixime			
Cefuroxime			
Cephalexin			
Cephalosporins		<b>S</b>	
Ciprofloxacin			
Clindamycin	<b>S</b>		

Medication	Viridans Group Strep	Coagulase Negative Staph	Escherichia coli
Doxycycline			
Erythromycin			
Fluconazole			
Fosfomycin			S
Levofloxacin			
Linezolid	S	S	
Nitrofurantoin			S
Ofloxacin			
Rifampin			
Sulfamethoxazole/Trimethoprim			
Tetracycline		S	
Trimethoprim/Sulfa			
Vancomycin		S	

Final Report Electronically signed by: Julia Bruggemann on 11/19/2022 at 01:34 PM

**Laboratory Director:** Dr. Nicole Massoll, M.D.



This test performed by Promus Diagnostics LLC, 2300 Dean Way, Suite 130, Southlake, TX 76092 CLIA#: 45D2156626; CAP#: 8412352

Please note: The semi-quantitative results for this test are based on estimates from internal validation studies performed at Promus Diagnostics and the scientific literature. These are intended to aid in guiding diagnostic and therapeutic decisions. Because of the increased sensitivity of PCR amplification used in this test compared to microbial culture, these results (genome copies / ml) may be a more accurate estimate of the actual concentration of pathogens than the results from agar-based cultures. However, treatment protocols should be based on the patient's clinical history, all associated laboratory test results, and the Guidelines from the Infectious Disease Society of America (IDSA) - Nicolle LE et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. Clin Infect Dis 2019 Mar 21; [e-pub]. (<https://doi.org/10.1093/cid/ciy1121>). This test was developed and its performance characteristics determined by Promus Diagnostics, LLC. It has not been cleared or approved by the FDA. However, such approval/clearance is not required, as the laboratory is regulated and qualified under CLIA to perform High - Complexity testing. This test is used for clinical purposes, and should not be regarded as investigational or for research.

The treatment guidance listed in the report is based upon infectious disease treatment references, the organisms detected, and genes known to contribute to medication resistance. Important clinical information such as comorbidities, renal function, patient weight, platelet count, microbiology results, etc. may influence the overall appropriateness of therapy. The provided guidance only takes drug allergies into account when they are provided and available to the pharmacist making the recommendation. The overall appropriateness of therapy must be determined by the physician treating the patient. The provider has all the information necessary to make that determination and should take the entire clinical presentation into account when making treatment decisions. Should the treating physician wish to discuss the provided guidance, the pharmacist is available for consult at the email and phone number provided.

Name: Lab Accession Number: D223220048 DOB: 6/12/1955

Report Date: 11/19/2022

## Tested Assay Results

### Panel: Urinary Tract Infection(UTI)

Organism	Results	Qualitative	Normal Reference Range
Acinetobacter baumannii	Not Detected	Negative	Not Detected
Actinobaculum schaalii	Not Detected	Negative	Not Detected
Aerococcus urinae	Not Detected	Negative	Not Detected
Candida albicans	Not Detected	Negative	Not Detected
Candida auris	Not Detected	Negative	Not Detected
Candida glabrata	Not Detected	Negative	Not Detected
Candida parapsilosis	Not Detected	Negative	Not Detected
Citrobacter freundii	Not Detected	Negative	Not Detected
Citrobacter koseri	Not Detected	Negative	Not Detected
Corynebacterium riegelii	Not Detected	Negative	Not Detected
Enterobacter aerogenes	Not Detected	Negative	Not Detected
Enterobacter cloacae	Not Detected	Negative	Not Detected
Enterococcus faecalis	Not Detected	Negative	Not Detected
Enterococcus faecium	Not Detected	Negative	Not Detected
Klebsiella oxytoca	Not Detected	Negative	Not Detected
Klebsiella pneumoniae	Not Detected	Negative	Not Detected
Morganella morganii	Not Detected	Negative	Not Detected
Mycoplasma hominis	Not Detected	Negative	Not Detected
Pantoea agglomerans	Not Detected	Negative	Not Detected
Proteus mirabilis	Not Detected	Negative	Not Detected
Proteus vulgaris	Not Detected	Negative	Not Detected
Providencia stuartii	Not Detected	Negative	Not Detected
Pseudomonas aeruginosa	Not Detected	Negative	Not Detected
Serratia marcescens	Not Detected	Negative	Not Detected
Staphylococcus aureus	Not Detected	Negative	Not Detected
Streptococcus agalactiae	Not Detected	Negative	Not Detected
Ureaplasma urealyticum	Not Detected	Negative	Not Detected
<b>Viridans Group Strep</b>	<b>Detected</b>	<b>Medium</b>	10 <sup>4</sup> - 10 <sup>5</sup>
<b>Coagulase Negative Staph</b>	<b>Detected</b>	<b>Low*</b>	<10 <sup>4</sup>
<b>Escherichia coli</b>	<b>Detected</b>	<b>Low*</b>	<10 <sup>4</sup>

This test performed by Promus Diagnostics LLC, 2300 Dean Way, Suite 130, Southlake, TX 76092 CLIA#: 45D2156626; CAP#: 8412352

Please note: The semi-quantitative results for this test are based on estimates from internal validation studies performed at Promus Diagnostics and the scientific literature. These are intended to aid in guiding diagnostic and therapeutic decisions. Because of the increased sensitivity of PCR amplification used in this test compared to microbial culture, these results (genome copies / ml) may be a more accurate estimate of the actual concentration of pathogens than the results from agar-based cultures. However, treatment protocols should be based on the patients clinical history, all associated laboratory test results, and the Guidelines from the Infectious Disease Society of America (IDSA) Nicole LE et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. Clin Infect Dis 2019 Mar 21; [e-pub]. (<https://doi.org/10.1093/cid/ciy1121>). This test was developed and its performance characteristics determined by Promus Diagnostics, LLC. It has not been cleared or approved by the FDA. However, such approval/ clearance is not required, as the laboratory is regulated and qualified under CLIA to perform High - Complexity testing. This test is used for clinical purposes, and should not be regarded as investigational or for research

The treatment guidance listed in the report is based upon infectious disease treatment references, the organisms detected, and genes known to contribute to medication resistance. Important

clinical information such as comorbidities, renal function, patient weight, platelet count, microbiology results, etc. may influence the overall appropriateness of therapy. The provided guidance only takes drug allergies into account when they are provided and available to the pharmacist making the recommendation. The overall appropriateness of therapy must be determined by the physician treating the patient. The provider has all the information necessary to make that determination and should take the entire clinical presentation into account when making treatment decisions. Should the treating physician wish to discuss the provided guidance, the pharmacist is available for consult at the email and phone number provided.

This test was developed and its performance characteristics determined by Promus Diagnostics LLC. It has not been cleared or approved by the FDA. However, such approval/clearance is not required, as the laboratory is regulated and qualified under CLIA to perform high-complexity testing. This test is used for clinical purposes, and should not be regarded as investigational or for research.

Name: Lab Accession Number: D223220048 DOB: 6/12/1955

Report Date: 11/19/2022

## Tested Assay Results

### Panel: Antibiotic Resistance Genes

Resistance Gene(s)	Antibiotic Class	Results	Normal Reference Range
ACC	Beta-Lactamase - Class C Type	Not Detected	Not Detected
ampC	Beta-Lactamase - Class C Type	Not Detected	Not Detected
BIL/LAT/CMY	Beta-Lactamase - Class C Type	Not Detected	Not Detected
CTX-M group 1, CTX-M group 2, CTX-M group 9, CTX-M group 8/25	Beta-Lactamase - Class A Type	Not Detected	Not Detected
DHA	Beta-Lactamase - Class C Type	Not Detected	Not Detected
FOX	Beta-Lactamase - Class C Type	Not Detected	Not Detected
IMP-1 group, IMP-16, IMP-7	Beta-Lactamase - Class B Type	Not Detected	Not Detected
KPC	Beta-Lactamase - Class A Type	Not Detected	Not Detected
MOX/CMY	Beta-Lactamase - Class C Type	Not Detected	Not Detected
OXA-1, GES, PER-1, PER-2	Extended Spectrum BetaLactamase - Class A	Not Detected	Not Detected
OXA-23, OXA-72, OXA-40, blaOXA-48	Beta-Lactamase - Class D Type (Carbapenemase / Oxacillinase)	Not Detected	Not Detected
PER-1, PER-2	Extended Spectrum BetaLactamase - Class A	Not Detected	Not Detected
QnrA, QnrS, Qnr B	Fluoroquinolones	Not Detected	Not Detected
SHV	Beta-Lactamase - Class A Type	Not Detected	Not Detected
vanA1, vanA2, vanB	Vancomycin	Not Detected	Not Detected
VEB	Extended Spectrum BetaLactamase - Class A	Not Detected	Not Detected
VIM	Beta-Lactamase - Class B Type	Not Detected	Not Detected
<b>dfrA5, dfrA1</b>	<b>Trimethoprim</b>	<b>Detected</b>	Not Detected
<b>mecA</b>	<b>Methicillin</b>	<b>Detected</b>	Not Detected
<b>Sul1, Sul2</b>	<b>Sulfonamide (Sulfamethoxazole)</b>	<b>Detected</b>	Not Detected
<b>TEM</b>	<b>Beta-Lactamase - Class A Type</b>	<b>Detected</b>	Not Detected

This test performed by Promus Diagnostics LLC, 2300 Dean Way, Suite 130, Southlake, TX 76092 CLIA#: 45D2156626; CAP#: 8412352

Please note: The semi-quantitative results for this test are based on estimates from internal validation studies performed at Promus Diagnostics and the scientific literature. These are intended to aid in guiding diagnostic and therapeutic decisions. Because of the increased sensitivity of PCR amplification used in this test compared to microbial culture, these results (genome copies / ml) may be a more accurate estimate of the actual concentration of pathogens than the results from agar-based cultures. However, treatment protocols should be based on the patients clinical history, all associated laboratory test results, and the Guidelines from the Infectious Disease Society of America (IDSA) Nicolle LE et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. Clin Infect Dis 2019 Mar 21;[e-pub]. (<https://doi.org/10.1093/cid/ciy1121>). This test was developed and its performance characteristics determined by Promus Diagnostics, LLC. It has not been cleared or approved by the FDA. However, such approval/ clearance is not required, as the laboratory is regulated and qualified under CLIA to perform High - Complexity testing. This test is used for clinical purposes, and should not be regarded as investigational or for research

The treatment guidance listed in the report is based upon infectious disease treatment references, the organisms detected, and genes known to contribute to medication resistance. Important clinical information such as comorbidities, renal function, patient weight, platelet count, microbiology results, etc. may influence the overall appropriateness of therapy. The provided guidance only takes drug allergies into account when they are provided and available to the pharmacist making the recommendation. The overall appropriateness of therapy must be determined by the physician treating the patient. The provider has all the information necessary to make that determination and should take the entire clinical presentation into account when making treatment decisions. Should the treating physician wish to discuss the provided guidance, the pharmacist is available for consult at the email and phone number provided.

This test was developed and its performance characteristics determined by Promus Diagnostics LLC. It has not been cleared or approved by the FDA. However, such approval/ clearance is not required, as the laboratory is regulated and qualified under CLIA to perform high-complexity testing. This test is used for clinical purposes, and should not be regarded as investigational or for research.

Patient Information

Specimen Information

Facility Information

# SAMPLE REPORT #7

Facility Name:  
Provider Name:  
Address:

\*Antibiotic therapy is not indicated if pathogen(s) are detected at Low quantities. However, all clinical information should be considered when treatment decisions are made.

## Panel: Urinary Tract Infection (UTI) Panel, NAAT

Organism(s) Detected	Results	Semi-Quantitative (High / Medium / Low)	Est. Microbial Load* (CFU/mL)
Klebsiella pneumoniae	Detected	High	>10 <sup>5</sup>
Viridans Group Strep	Detected	Low*	<10 <sup>4</sup>

## Panel: Antibiotic Resistance Genes

Resistance Gene(s) Detected	Antibiotic Class	Results
SHV	Beta-Lactamase - Class A Type	Beta Lactam Resistance Detected

### ANTIBIOTIC TREATMENT OPTIONS

**S**

= Pathogen Detected is Sensitive to this Antibiotic Treatment

Medication	Klebsiella pneumoniae	Viridans Group Strep
Amoxicillin		
Amoxicillin-Clavulanate		
Ampicillin		
Azithromycin		
Cefadroxil		
Cefdinir		
Cefixime		
Cefuroxime		
Cephalexin		
Cephalosporins		
Ciprofloxacin		
Clindamycin		<b>S</b>
Doxycycline		
Erythromycin		
Fluconazole		
Fosfomycin	<b>S</b>	

Medication	Klebsiella pneumoniae	Viridans Group Strep
Levofloxacin		
Linezolid		S
Nitrofurantoin	S	
Ofloxacin		
Rifampin		
Sulfamethoxazole/Trimethoprim		
Tetracycline		
Trimethoprim/Sulfa	S	
Vancomycin		

Final Report Electronically signed by: Julia Bruggemann on 11/19/2022 at 03:29 PM

**Laboratory Director:** Dr. Nicole Massoll, M.D.



This test performed by Promus Diagnostics LLC, 2300 Dean Way, Suite 130, Southlake, TX 76092 CLIA#: 45D2156626; CAP#: 8412352

Please note: The semi-quantitative results for this test are based on estimates from internal validation studies performed at Promus Diagnostics and the scientific literature. These are intended to aid in guiding diagnostic and therapeutic decisions. Because of the increased sensitivity of PCR amplification used in this test compared to microbial culture, these results (genome copies / ml) may be a more accurate estimate of the actual concentration of pathogens than the results from agar-based cultures. However, treatment protocols should be based on the patient's clinical history, all associated laboratory test results, and the Guidelines from the Infectious Disease Society of America (IDSA) - Nicolle LE et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. Clin Infect Dis 2019 Mar 21; [e-pub]. (<https://doi.org/10.1093/cid/ciy1121>). This test was developed and its performance characteristics determined by Promus Diagnostics, LLC. It has not been cleared or approved by the FDA. However, such approval/clearance is not required, as the laboratory is regulated and qualified under CLIA to perform High - Complexity testing. This test is used for clinical purposes, and should not be regarded as investigational or for research.

The treatment guidance listed in the report is based upon infectious disease treatment references, the organisms detected, and genes known to contribute to medication resistance. Important clinical information such as comorbidities, renal function, patient weight, platelet count, microbiology results, etc. may influence the overall appropriateness of therapy. The provided guidance only takes drug allergies into account when they are provided and available to the pharmacist making the recommendation. The overall appropriateness of therapy must be determined by the physician treating the patient. The provider has all the information necessary to make that determination and should take the entire clinical presentation into account when making treatment decisions. Should the treating physician wish to discuss the provided guidance, the pharmacist is available for consult at the email and phone number provided.



Name: Lab Accession Number: D223220043 DOB: 10/17/1949

Report Date: 11/19/2022

## Tested Assay Results

### Panel: Urinary Tract Infection(UTI)

Organism	Results	Qualitative	Normal Reference Range
Acinetobacter baumannii	Not Detected	Negative	Not Detected
Actinobaculum schaalii	Not Detected	Negative	Not Detected
Aerococcus urinae	Not Detected	Negative	Not Detected
Candida albicans	Not Detected	Negative	Not Detected
Candida auris	Not Detected	Negative	Not Detected
Candida glabrata	Not Detected	Negative	Not Detected
Candida parapsilosis	Not Detected	Negative	Not Detected
Citrobacter freundii	Not Detected	Negative	Not Detected
Citrobacter koseri	Not Detected	Negative	Not Detected
Coagulase Negative Staph	Not Detected	Negative	Not Detected
Corynebacterium riegelii	Not Detected	Negative	Not Detected
Enterobacter aerogenes	Not Detected	Negative	Not Detected
Enterobacter cloacae	Not Detected	Negative	Not Detected
Enterococcus faecalis	Not Detected	Negative	Not Detected
Enterococcus faecium	Not Detected	Negative	Not Detected
Escherichia coli	Not Detected	Negative	Not Detected
Klebsiella oxytoca	Not Detected	Negative	Not Detected
Morganella morganii	Not Detected	Negative	Not Detected
Mycoplasma hominis	Not Detected	Negative	Not Detected
Pantoea agglomerans	Not Detected	Negative	Not Detected
Proteus mirabilis	Not Detected	Negative	Not Detected
Proteus vulgaris	Not Detected	Negative	Not Detected
Providencia stuartii	Not Detected	Negative	Not Detected
Pseudomonas aeruginosa	Not Detected	Negative	Not Detected
Serratia marcescens	Not Detected	Negative	Not Detected
Staphylococcus aureus	Not Detected	Negative	Not Detected
Streptococcus agalactiae	Not Detected	Negative	Not Detected
Ureaplasma urealyticum	Not Detected	Negative	Not Detected
<b>Klebsiella pneumoniae</b>	<b>Detected</b>	<b>High</b>	>10 <sup>5</sup>
<b>Viridans Group Strep</b>	<b>Detected</b>	<b>Low*</b>	<10 <sup>4</sup>

This test performed by Promus Diagnostics LLC, 2300 Dean Way, Suite 130, Southlake, TX 76092 CLIA#: 45D2156626; CAP#: 8412352

Please note: The semi-quantitative results for this test are based on estimates from internal validation studies performed at Promus Diagnostics and the scientific literature. These are intended to aid in guiding diagnostic and therapeutic decisions. Because of the increased sensitivity of PCR amplification used in this test compared to microbial culture, these results (genome copies / ml) may be a more accurate estimate of the actual concentration of pathogens than the results from agar-based cultures. However, treatment protocols should be based on the patients clinical history, all associated laboratory test results, and the Guidelines from the Infectious Disease Society of America (IDSA) Nicolle LE et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. Clin Infect Dis 2019 Mar 21;[e-pub]. (<https://doi.org/10.1093/cid/ciy1121>). This test was developed and its performance characteristics determined by Promus Diagnostics, LLC. It has not been cleared or approved by the FDA. However, such approval/ clearance is not required, as the laboratory is regulated and qualified under CLIA to perform High - Complexity testing. This test is used for clinical purposes, and should not be regarded as investigational or for research

The treatment guidance listed in the report is based upon infectious disease treatment references, the organisms detected, and genes known to contribute to medication resistance. Important

clinical information such as comorbidities, renal function, patient weight, platelet count, microbiology results, etc. may influence the overall appropriateness of therapy. The provided guidance only takes drug allergies into account when they are provided and available to the pharmacist making the recommendation. The overall appropriateness of therapy must be determined by the physician treating the patient. The provider has all the information necessary to make that determination and should take the entire clinical presentation into account when making treatment decisions. Should the treating physician wish to discuss the provided guidance, the pharmacist is available for consult at the email and phone number provided.

This test was developed and its performance characteristics determined by Promus Diagnostics LLC. It has not been cleared or approved by the FDA. However, such approval/clearance is not required, as the laboratory is regulated and qualified under CLIA to perform high-complexity testing. This test is used for clinical purposes, and should not be regarded as investigational or for research.

Name: Lab Accession Number: D223220043 DOB: 10/17/1949

Report Date: 11/19/2022

## Tested Assay Results

### Panel: Antibiotic Resistance Genes

Resistance Gene(s)	Antibiotic Class	Results	Normal Reference Range
ACC	Beta-Lactamase - Class C Type	Not Detected	Not Detected
ampC	Beta-Lactamase - Class C Type	Not Detected	Not Detected
BIL/LAT/CMY	Beta-Lactamase - Class C Type	Not Detected	Not Detected
CTX-M group 1, CTX-M group 2, CTX-M group 9, CTX-M group 8/25	Beta-Lactamase - Class A Type	Not Detected	Not Detected
dfrA5, dfrA1	Trimethoprim	Not Detected	Not Detected
DHA	Beta-Lactamase - Class C Type	Not Detected	Not Detected
FOX	Beta-Lactamase - Class C Type	Not Detected	Not Detected
IMP-1 group, IMP-16, IMP-7	Beta-Lactamase - Class B Type	Not Detected	Not Detected
KPC	Beta-Lactamase - Class A Type	Not Detected	Not Detected
mecA	Methicillin	Not Detected	Not Detected
MOX/CMY	Beta-Lactamase - Class C Type	Not Detected	Not Detected
OXA-1, GES, PER-1, PER-2	Extended Spectrum BetaLactamase - Class A	Not Detected	Not Detected
OXA-23, OXA-72, OXA-40, blaOXA-48	Beta-Lactamase - Class D Type (Carbapenemase / Oxacillinase)	Not Detected	Not Detected
PER-1, PER-2	Extended Spectrum BetaLactamase - Class A	Not Detected	Not Detected
QnrA, QnrS, Qnr B	Fluoroquinolones	Not Detected	Not Detected
Sul1, Sul2	Sulfonamide (Sulfamethoxazole)	Not Detected	Not Detected
TEM	Beta-Lactamase - Class A Type	Not Detected	Not Detected
vanA1, vanA2, vanB	Vancomycin	Not Detected	Not Detected
VEB	Extended Spectrum BetaLactamase - Class A	Not Detected	Not Detected
VIM	Beta-Lactamase - Class B Type	Not Detected	Not Detected
<b>SHV</b>	<b>Beta-Lactamase - Class A Type</b>	<b>Detected</b>	Not Detected

This test performed by Promus Diagnostics LLC, 2300 Dean Way, Suite 130, Southlake, TX 76092 CLIA#: 45D2156626; CAP#: 8412352

Please note: The semi-quantitative results for this test are based on estimates from internal validation studies performed at Promus Diagnostics and the scientific literature. These are intended to aid in guiding diagnostic and therapeutic decisions. Because of the increased sensitivity of PCR amplification used in this test compared to microbial culture, these results (genome copies / ml) may be a more accurate estimate of the actual concentration of pathogens than the results from agar-based cultures. However, treatment protocols should be based on the patient's clinical history, all associated laboratory test results, and the Guidelines from the Infectious Disease Society of America (IDSA) Nicole LE et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. Clin Infect Dis 2019 Mar 21;[e-pub]. (<https://doi.org/10.1093/cid/ciy1121>). This test was developed and its performance characteristics determined by Promus Diagnostics, LLC. It has not been cleared or approved by the FDA. However, such approval/clearance is not required, as the laboratory is regulated and qualified under CLIA to perform High - Complexity testing. This test is used for clinical purposes, and should not be regarded as investigational or for research.

The treatment guidance listed in the report is based upon infectious disease treatment references, the organisms detected, and genes known to contribute to medication resistance. Important clinical information such as comorbidities, renal function, patient weight, platelet count, microbiology results, etc. may influence the overall appropriateness of therapy. The provided guidance only takes drug allergies into account when they are provided and available to the pharmacist making the recommendation. The overall appropriateness of therapy must be determined by the physician treating the patient. The provider has all the information necessary to make that determination and should take the entire clinical presentation into account when making treatment decisions. Should the treating physician wish to discuss the provided guidance, the pharmacist is available for consult at the email and phone number provided.

This test was developed and its performance characteristics determined by Promus Diagnostics LLC. It has not been cleared or approved by the FDA. However, such approval/clearance is not required, as the laboratory is regulated and qualified under CLIA to perform high-complexity testing. This test is used for clinical purposes, and should not be regarded as investigational or for research.